LONDON, Sept 24, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it has appointed former US Food and Drug Administration Commissioner, Dr. David Kessler, as a strategic advisor.

Dr. Kessler was the FDA Commissioner under presidents George H. W. Bush and Bill Clinton, where he directed a number of new programs including the regulation of marketing and sale of tobacco products to children and nutrition labeling for food. He is a graduate of Amherst College, the University of Chicago Law School, and Harvard Medical School, and has been the dean of the medical schools at Yale and the University of California, San Francisco. He currently serves on the board of various organizations including the National Center for Addiction and Substance Abuse at Columbia University as well as Drug Strategies, a non-profit research institute that promotes more effective drug abuse prevention, education and treatment.

"We are very pleased to add Dr. Kessler as a strategic advisor," said Dr. Roger Crystal, Chief Executive Officer of Lightlake. "With his wide range of experience in research, clinical medicine, education, administration, and law, Dr. Kessler will be a tremendous guide for us as we work to develop a range of treatments to common addictive disorders. Specifically, Dr. Kessler's major involvement with us will be to advise on the side-effects of addiction."